Circulating microRNA-based screening tool for breast cancer

[en] Circulating microRNAs (miRNAs) are increasingly recognized as powerful biomarkers in several pathologies, including breast cancer. Here, their plasmatic levels were measured to be used as an alternative screening procedure to mammography for breast cancer diagnosis. A plasma miRNA profile was determined by RT-qPCR in a cohort of 378 women. A diagnostic model was designed based on the expression of 8 miRNAs measured first in a profiling cohort composed of 41 primary breast cancers and 45 controls, and further validated in diverse cohorts composed of 108 primary breast cancers, 88 controls, 35 breast cancers in remission, 31 metastatic breast cancers and 30 gynecologic tumors. A receiver operating characteristic curve derived from the 8-miRNA random forest based diagnostic tool exhibited an area under the curve of 0.81. The accuracy of the diagnostic tool remained unchanged considering age and tumor stage. The miRNA signature correctly identified patients with metastatic breast cancer. The use of the classification model on cohorts of patients with breast cancers in remission and with gynecologic cancers yielded prediction distributions similar to that of the control group. Using a multivariate supervised learning method and a set of 8 circulating miRNAs, we designed an accurate, minimally invasive screening tool for breast cancer.

Research center :

Giga-Cancer - ULiège
Giga-Genetics - ULiège

Disciplines :

Genetics & genetic processes

Author, co-author :

Freres, Pierre ^✱; Université de Liège > Département des sciences cliniques > Oncologie

Wenric, Stéphane ^✱; Université de Liège > Département des sciences cliniques > Oncologie

BOUKERROUCHA, Meriem ; Université de Liège - ULiège > GIGA-Research > Laboratory of Human Genetics

Fasquelle, Corinne ; Université de Liège > Département des sciences biomédicales et précliniques > GIGA-R : Génétique humaine

Thiry, Jérôme ; Université de Liège > Département des sciences cliniques > Oncologie

Bovy, Nicolas ; Université de Liège - ULiège > GIGA-Research > Laboratory of Molecular Angiogenesis

Struman, Ingrid ; Université de Liège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire

Geurts, Pierre ; Université de Liège > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Algorith. des syst. en interaction avec le monde physique

COLLIGNON, Joëlle ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

SCHROEDER, Hélène ; Centre Hospitalier Universitaire de Liège - CHU > Centre d'oncologie

More authors (6 more)

^✱ These authors have contributed equally to this work.

Language :

English

Title :

Circulating microRNA-based screening tool for breast cancer

Publication date :

29 December 2015

Journal title :

Oncotarget

eISSN :

1949-2553

Publisher :

Impact Journals, Albany, United States - New York

Peer reviewed :

Peer Reviewed verified by ORBi

Funders :

F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]
FWB - Fédération Wallonie-Bruxelles [BE]
Télévie [BE]
CHU Liège - Centre Hospitalier Universitaire de Liège [BE]
Region Wallone (Secance, BRAMIR)

Available on ORBi :

since 30 January 2016

Statistics

Number of views

218 (56 by ULiège)

Number of downloads

201 (20 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Jemal A, Bray F, Center, Melissa M., Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
Bleyer A, Welch HG. Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence. N Engl J Med. 2012; 367:1998-2005.
Kohn L, Mambourg F, Robays J, Albertijn M, Janssens J, Hoefnagels K, Ronsmans M, Jonckheer P. Informed choice on breast cancer screening: messages to support informed decision. Good Clinical Practice (GCP) Brussels: Belgian Health Care Knowledge Centre (KCE). 2014. KCE Reports 216. D/2014/10.273/03.
Eulalio A, Huntzinger E, Izaurralde E. Getting to the Root of miRNA-Mediated Gene Silencing. Cell. 2008; 132:9-14.
Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009; 19:92-105.
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-97.
Ambros V. The functions of animal microRNAs. Nature. 2004; 431:350-5.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, et al. MicroRNA expression profiles classify human cancers. Nature. 2005; 435:834-838.
Mathivanan S, Ji H, Simpson RJ. Exosomes: Extracellular organelles important in intercellular communication. Journal of Proteomics. 2010; 73:1907-20.
Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Science. 2010; 101:2087-92.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008; 105:10513-8.
Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, Tan PH, Ho GH, Lee AS-G. Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res. 2013; 19:4477-87.
Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, Arlt D, Rath M, Sohn C, Benner A, Junkermann H, Schneeweiss A, Burwinkel B. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer. 2013; 132:1602-12.
Guo L, Zhao Y, Yang S, Cai M, Wu Q, Chen F. Genome-wide screen for aberrantly expressed miRNAs reveals miRNA profile signature in breast cancer. Mol Biol Rep. 2013; 40:2175-86.
Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ. Systemic miRNA-195 Differentiates Breast Cancer from Other Malignancies and Is a Potential Biomarker for Detecting Noninvasive and Early Stage Disease. The Oncologist. 2010; 15:673-82.
Hu Z, Dong J, Wang L-E, Ma H, Liu J, Zhao Y, Tang J, Chen X, Dai J, Wei Q, Zhang C, Shen H. Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis. 2012; 33:828-34.
Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS, Ditzel HJ. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study. Mol Oncol. 2014; 8:874-83.
Leidner RS, Li L, Thompson CL. Dampening enthusiasm for circulating microRNA in breast cancer. PLoS One. 2013; 8:e57841.
Ng EKO, Li R, Shin VY, Jin HC, Leung CPH, Ma ESK, Pang R, Chua D, Chu KM, Law WL, Law SYK, Poon RTP, Kwang A. Circulating microRNAs as Specific Biomarkers for Breast Cancer Detection. PLoS One. 2013; 8:e53141.
Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 2010; 12:R90.
Shen J, Hu Q, Schrauder M, Yan L, Wang D, Medico L, Guo Y, Yao S, Zhu Q, Liu B, Qin M, Beckmann MW, Fasching PA, et al. Circulating miR-148b and miR-133a as biomarkers for breast cancer detection. Oncotarget. 2014; 5:5284. doi:10.18632/oncotarget.2014.
Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecologic Oncology. 2010; 119:586-93.
Wu Q, Wang C, Lu Z, Guo L, Ge Q. Analysis of serum genome-wide microRNAs for breast cancer detection. Clinica Chimica Acta. 2012; 413:1058-65.
Zearo S, Kim E, Zhu Y, Zhao JT, Sidhu SB, Robinson BG, Soon PSH. MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers. BMC Cancer. 2014; 14:200.
Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One. 2010; 5:e13735.
Zhu J, Zheng Z, Wang J, Sun J, Wang P, Cheng X, Fu L, Zhang L, Wang Z, Li Z. Different miRNA expression profiles between human breast cancer tumors and serum. Front Genet. 2014; 5:149.
Stückrath I, Rack B, Janni W, Jäger B, Pantel K, Schwarzenbach H. Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients. Oncotarget. 2015; 6:13387. doi:10.18632/oncotarget.3874.
Schrauder MG, Strick R, Schulz-Wendtland R. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One. 2012; 7:e29770.
Cookson VJ, Bentley MA, Hogan B V, Horgan K, Hayward BE, Hazelwood LD, Hughes TA. Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. Cell Oncol. 2012; 35:301-8.
Breiman L. Random Forests. Machine Learning. 2001; 45: 5-32.
Geurts P, Fillet M, de Seny D, Meuwis M-A, Malaise M, Merville M-P, Wehenkel L. Proteomic mass spectra classification using decision tree based ensemble methods. Bioinformatics. 2005; 21:3138-45.
Pisano ED, Gatsonis C, Ph D, Hendrick E, Yaffe M, Baum JK, Acharyya S, Conant EF, Fajardo LL, Bassett L, Orsi CD, Jong R, Rebner M. Diagnostic Performance of Digital versus Film Mammography for Breast-Cancer Screening. N Engl J Med. 2005; 353:1773-83.
Gion M, Mione R, Leon AE, Lüftner D, Molina R, Possinger K, Robertson JF. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer. 2001; 37:355-363.
Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. British Journal of Cancer. 2013; 108:2205-40.
Yankaskas BC, Taplin SH, Ichikawa L, Geller BM, Rosenberg RD, Carney PA, Kerlikowske K, Ballard-Barbash R, Cutter GR, Barlow WE. Association between mammography timing and measures of screening performance in the United States. Radiology. 2005; 234:363-73.
Théberge I, Chang S-L, Vandal N, Daigle J-M, Guertin M-H, Pelletier E, Brisson J. Radiologist interpretive volume and breast cancer screening accuracy in a Canadian organized screening program. J Natl Cancer Inst. 2014; 106:djt461.
Cheng L, Doecke JD, Sharples RA, Villemagne VL, Fowler CJ, Rembach a, Martins RN, Rowe CC, Macaulay SL, Masters CL, Hill AF. Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment. Mol Psychiatry. 2014:1-9.
Hemphill E, Lindsay J, Lee C, Mandoiu II. Feature selection and classifier performance on diverse bio-logical datasets. BMC Bioinformatics. 2014; 15:S4.
Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, Vandesompele J. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009; 10:R64.
Janaki Ramaiah M, Lavanya A, Honarpisheh M, Zarea M, Bhadra U, Bhadra MP. MiR-15/16 complex targets p70S6 kinase 1 and controls cell proliferation in MDA-MB-231 breast cancer cells. Gene. 2014; 552:255-64.
Büssing I, Slack FJ, Großhans H. let-7 microRNAs in development, stem cells and cancer. Trends in Molecular Medicine. 2008; 14:400-9.
Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T, Parenti AR, Daidone MG, Bicciato S, et al. A MicroRNA targeting dicer for metastasis control. Cell. 2010; 141: 1195-207.
Olive V, Sabio E, Bennett MJ, De Jong CS, Biton A, McGann JC, Greaney SK, Sodir NM, Zhou AY, Balakrishnan A, Foth M, Luftig MA, Goga A, et al. A component of the mir-17-92 polycistronic oncomir promotes oncogene-dependent apoptosis. Elife. 2013; 2:e00822.
Tao S, He H, Chen Q, Yue W. GPER mediated estradiol reduces miR-148a to promote HLA-G expression in breast cancer. Biochem Biophys Res Commun. 2014; 451:74-8.
Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT. The MIQE guidelines: minimum information for publication of quantitative realtime PCR experiments. Clin Chem. 2009; 55:611-22.
Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010; 50:298-301.
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nature Protocols. 2008; 3: 1101-8.
Blondal T, Jensby Nielsen S, Baker A, Andreasen D, Mouritzen P, Wrang Teilum M, Dahlsveen IK. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods. 2013; 59:S1-6.
Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Ser B. 1995; 57:289-300.
Liaw A, Wiener M. Classification and regression by randomForest. R news. 2002; 2:18-22.
Genuer R, Poggi J-M, Tuleau-Malot C. Variable selection using random forests. Pattern Recognition Letters. 2010; 31:2225-36.
Saeys Y, Inza I, Larrañaga P. A review of feature selection techniques in bioinformatics. Bioinformatics. 2007; 23:2507-17.
Díaz-Uriarte R, de Andrés SA. Gene selection and classification of microarray data using random forest. BMC Bioinformatics. 2006; 7:3.
Ghattas B, Ben Ishak A. Sélection de variables pour la classification binaire en grande dimension: comparaisons et application aux données de biopuces. Journal de la société française de statistiques. 2008; 149:43-66.